Paper Details

  1. Home
  2. Paper Details

Cyclosporine A for induction of remission in severe ulcerative colitis.

Author: BrezisM, RegushevskayaE, ShiboletO, Soares-WeiserK

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Ulcerative colitis (UC) is a chronic condition with periods of remission and flare-ups. About 15% of patients experience severe flare-ups that require hospitalization. While IV steroids are the usual treatment (effective in 60% of cases), those who don't respond often need surgery to remove the colon. Cyclosporine-A (CsA) is a newer treatment that offers an alternative to surgery. It works by suppressing the immune system, but unlike other immunosuppressants, it acts quickly and doesn't suppress bone marrow function. This review examines the effectiveness and safety of CsA for severe UC.
Paper Details　
Original Abstract of the Article :
Ulcerative colitis (UC) is characterized by a life-long chronic course with remissions and exacerbations. Approximately 15% of patients have a severe attack requiring hospitalization at some time during their illness. These patients are traditionally treated with intravenous corticosteroids, with a ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD004277.pub2

データ提供：米国国立医学図書館（NLM）

Cyclosporine A for Severe Ulcerative Colitis: A Promising Treatment

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by inflammation and ulcers in the colon. Imagine a camel traversing a desolate desert landscape, experiencing a burning sensation in its gut. This is a painful and debilitating experience for those suffering from ulcerative colitis.

This study investigates the use of cyclosporine A (CsA) for inducing remission in patients with severe UC. Researchers are seeking a safe and effective way to quell the inflammation and alleviate the pain, offering these camels relief from their discomfort. The study found that CsA was effective in inducing remission in a significant number of patients. It's like finding an oasis in the desert, providing a much-needed respite from the pain and inflammation.

Cyclosporine A: An Oasis in the Desert of Ulcerative Colitis

This study highlights the potential benefits of cyclosporine A (CsA) in treating severe ulcerative colitis. The findings offer hope for patients struggling with this condition, potentially improving their quality of life and offering a path toward remission.

Navigating the Desert of UC: Finding Relief and Hope

Ulcerative colitis can be a challenging and debilitating condition. This study provides valuable insights into the use of cyclosporine A (CsA) as a potential treatment option. It's important to consult with a healthcare professional to determine the best treatment plan for your individual needs. Just like a camel needs a reliable source of water to survive in the desert, individuals with ulcerative colitis need effective treatment options to manage their condition and find relief.

Dr. Camel's Conclusion

Cyclosporine A (CsA) offers a potential treatment option for patients with severe ulcerative colitis. The study's findings are promising, suggesting that this medication could provide relief from the pain and inflammation associated with this debilitating condition. Remember, just like a camel relies on its instincts to navigate a desert, we must trust in the power of research to discover new solutions for challenging health conditions.
Date :
  1. Date Completed 2005-05-27
  2. Date Revised 2018-12-21
Further Info :

Pubmed ID

15674937

DOI: Digital Object Identifier

10.1002/14651858.CD004277.pub2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.